French Biotech Enters New Agreement to Advance its IBD Immunotherapy – Labiotech.eu (blog)
|
French Biotech Enters New Agreement to Advance its IBD Immunotherapy
Labiotech.eu (blog) “We are pleased to advance our collaboration with Selexis with the initiation of a key step for our immunotherapy OSE-127 towards the clinical stage and its development in ulcerative colitis,” said Dominique Costantini, CEO of OSE Immunotherapeutics. |
